

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Meta-Analysis

**Manuscript NO:** 53591

**Title:** Treatment strategies and methods of prevention for drug-resistant *Helicobacter pylori*

**Reviewer's code:** 03474938

**Position:** Editorial Board

**Academic degree:** PhD

**Professional title:** Research Scientist

**Reviewer's country:** Mexico

**Author's country:** China

**Manuscript submission date:** 2019-12-26

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2019-12-28 00:46

**Reviewer performed review:** 2020-01-04 05:00

**Review time:** 7 Days and 4 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input checked="" type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

The topic is important and current. It would be very interesting and useful to include in the review a section an emphasis on differences between children and adults regarding treatment and resistance to antibiotics.

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☒ No

##### ***BPG Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☒ No

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Meta-Analysis

**Manuscript NO:** 53591

**Title:** Treatment strategies and methods of prevention for drug-resistant *Helicobacter pylori*

**Reviewer's code:** 00004403

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's country:** Italy

**Author's country:** China

**Manuscript submission date:** 2019-12-26

**Reviewer chosen by:** Jie Wang

**Reviewer accepted review:** 2020-01-04 09:29

**Reviewer performed review:** 2020-01-14 11:39

**Review time:** 10 Days and 2 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input type="checkbox"/> No

## **SPECIFIC COMMENTS TO AUTHORS**

This review on the treatment strategies and methods of prevention of eradication failures of anti-*Helicobacter* regimens has important drawbacks, as follows: - The authors have written a confusing paper, in which there are too many ideas and few experimental findings. Moreover, the sequence of concepts is not clear for the reader - The main problem in assessing the results of eradication therapy is represented by the antibiotic resistance, in particular claritromycin resistance. The authors do not mention the level of CLA resistance, which permits to predict a positive eradication in both western countries and in China. - According to the presence of high rates of CLA residence, the actual trend is towards the use of quadruple instead of triple therapy and to prolong the duration of every eradication scheme (10-14 days). These aspects are not discussed in the review. - In order to render the paper more clear, the authors should distinguish between non-bismuth and bismuth quadruple regimens - Moreover, the attention should be addressed to describing first-line therapies and then second- and third-line schemes in case of eradication failure of the first attempts - Antibiotic susceptibility tests are not practical in daily clinical practice and consequently they are poorly used - Some statements are highly questionable (x-ray documentation of gastric damage in Hp+ patients and association between Hp and diabetes). - Furazolidone is poorly used in western countries and produces important adverse events - Natural Chinese products can be interesting, but there are no clinical trials assessing their efficacy in comparison with traditional regimens in daily practice

## **INITIAL REVIEW OF THE MANUSCRIPT**

### ***Google Search:***

[ ] The same title



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

☐ Duplicate publication

☐ Plagiarism

☐ Yes ☐ No

***BPG Search:***

☐ The same title

☐ Duplicate publication

☐ Plagiarism

☐ Yes ☐ No

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Meta-Analysis

**Manuscript NO:** 53591

**Title:** Treatment strategies and methods of prevention for drug-resistant *Helicobacter pylori*

**Reviewer's code:** 00503623

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Professor

**Reviewer's country:** United States

**Author's country:** China

**Manuscript submission date:** 2019-12-26

**Reviewer chosen by:** Jie Wang

**Reviewer accepted review:** 2020-01-13 16:32

**Reviewer performed review:** 2020-01-14 19:19

**Review time:** 1 Day and 2 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

## **SPECIFIC COMMENTS TO AUTHORS**

The manuscript, no. 53591, according to the authors, presents the review of the current status and the progress in the approaches used in prevention and treatment of the drug-resistant Hp. While, the manuscript promotes rather extensively the use of traditional Chinese medicine, only few factual data are provided. Also, the long list of variety of claims made by the authors are not supported by the literature references. Another shortcoming of this paper is the total omission of the natural products and agents affecting TLR4 activation by Hp., as well as those affecting MAPK and IKK cascades(see Inflammopharmacology vol.27; 2019: 203-2011).

## **INITIAL REVIEW OF THE MANUSCRIPT**

### ***Google Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

### ***BPG Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No